Formulation & Delivery of Spray Dried Biologics for Nasal Dosage Forms

The nasal route has emerged as an attractive alternative to injectable delivery for a growing range of biologics, offering the potential for rapid systemic absorption, direct nose-to-brain delivery, and targeted immune responses. However, achieving effective and reproducible delivery requires more than simply formulating the active ingredient. Success depends on creating stable dry powder formulations with carefully engineered particle characteristics and selecting the right delivery device. 

In this whitepaper, Dr Richard Johnson, Chief Scientific Officer at Upperton, explores how spray drying has become the technology of choice for developing dry powder biologics for nasal administration. Learn how formulation, particle engineering, device selection, and aerodynamic testing work together to maximise stability, optimise deposition, and accelerate development towards clinical application.

Download this whitepaper to learn:

• Why interest in nasal delivery of biologics continues to grow across peptides, proteins, vaccines and oligonucleotides. 
• How spray drying creates stable dry powder formulations while preserving biological activity and molecular integrity. 
• The principles of particle engineering and how particle size influences nasal deposition and delivery performance. 
• The different nasal delivery targets, including systemic absorption, direct-to-brain delivery, and immune system activation. 
• How formulation screening, stability assessment, and aerodynamic testing support successful development programmes. 
• The role of integrated development platforms such as UpperNose™ in accelerating dry powder nasal drug development.